Indobufen in the prevention of thromboembolic complications in patients with heart disease. A randomized, placebo-controlled, double-blind study.

@article{Fornaro1993IndobufenIT,
  title={Indobufen in the prevention of thromboembolic complications in patients with heart disease. A randomized, placebo-controlled, double-blind study.},
  author={Gianluigi Fornaro and Plinio Rossi and Pier Giuseppe Mantica and Massimo Caccia and D Aralda and Maurizio Lavezzari and Franco Pamparana and Gloria Milanesi},
  journal={Circulation},
  year={1993},
  volume={87 1},
  pages={162-4}
}
BACKGROUND The purpose of this randomized, double-blind study was to evaluate the efficacy of indobufen, a reversible inhibitor of platelet cyclooxygenase, in the prevention of embolic events of cardiac origin. METHODS AND RESULTS One hundred ninety-six patients with heart disease and at risk for cardiogenic embolism (90 with atrial fibrillation and 106 in sinus rhythm) were randomly assigned to receive indobufen (100 mg b.i.d.) or placebo. All patients were reexamined every 3 months for the… CONTINUE READING